Prostate Cancer

... Threshold Announces Management Additions Threshold Announces Management Additions Michael Brawer, M.D.

Appointed Head of Urology Therapeutic Area Clinical, Regulatory and Manufacturing Vice Presidents Added REDWOOD CITY, Calif., March 28 /PRNewswire-FirstCall/ - Threshold Pharmaceuticals, Inc.

(Nasdaq: THLD), today announced that Michael Brawer, M.D.

has been named Urology Therapeutic Area Head.

Dr.

Brawer joins Threshold as a member of the management team and will lead the strategic product development for TH-070, the Company's late-stage product candidate for Benign Prostatic Hyperplasia (BPH), and help to identify additional genitourinary opportunities for Threshold.

In addition, the Company noted that during the past year it had continued to strengthen its development capabilities with the addition of three vice presidents to help manage the Company's clinical development programs, which include two phase 3 studies.

Dr.

Brawer, a consultant to Threshold Pharmaceuticals since 2004, has been the director of the Northwest Prostate Institute in Seattle, Washington since 1998.

He was formerly Professor of Urology and adjunct Professor of Pathology at the University of Washington.

"We are extremely pleased with Michael's commitment to Threshold," said Alan Colowick, chief medical officer.

"His knowledge and depth of understanding of the urology area has provided a great deal of insight into the treatment of BPH and the importance of...

... YM BioSciences' partner, Oncoscience AG, cleared for Phase III trial in Germany with nimotuzumab YM BioSciences' partner, Oncoscience AG, cleared for Phase III trial in Germany with nimotuzumab - Phase II results presented at the 27th Annual German Cancer Conference - MISSISSAUGA, ON, March 28 /PRNewswire-FirstCall/ - YM BioSciences Inc.

(AMEX:YMI, TSX:YM, AIM:YMBA), the cancer product development company, today announced that its partner, Oncoscience AG, has been cleared by the German regulatory authority for biological products, the Paul Ehrlich Institute, to initiate a Phase III trial of nimotuzumab in combination with radiation in children with inoperable pontine (brain stem) glioma.

The clinical trial was also reviewed with the EMEA and is designed as a prospectively registrable study on the basis of a single arm trial because of the absence of treatment options for children suffering from pontine glioma.

It is anticipated that marketing authorization subsequent to a successful trial would be sought under the EMEA centralized procedure.

The trial is a single arm study in which 40 children with inoperable pontine glioma will be treated with radiation concomitant with nimotuzumab.

The primary clinical endpoints in the trial will be Progression-Free Survival at 3, 6, 12 and 24 months with Median Survival as secondary endpoint.

Clinical sites will be located in Germany, Italy, Belarus and Russia and it is anticipated that recruitm...

...The dilemma for wives and significant others is how to get their men to the doctor.

Here are some suggestions from Mengel and other experts: - Don't start with the nagging.

Gently suggest that annual checkups are a reasonable and responsible thing to do, and leave it at that for now.

He needs time to get his head around the idea.

- Don't start by telling him how out of shape and unhealthy he is.

He knows these things.

This is precisely the reason he doesn't want to go to the doctor.

- Don't start with threats.

He'll just dig in his heels.

- Don't start with prophecies of doom and death.

This is another reason he won't go to the doctor.

He's scared.

He's afraid the doctor will tell him of his imminent doom and death.

He'd rather be surprised by these things.

- Appeal to his sense of responsibility as family provider and protector.

This tactic may take some time to work, but its chances of eventual success are high.

Most men cherish their role as provider and protector.

- Appeal to his love of his family.

Another good, though slow-acting, strategy.

- Clip articles and ads featuring sports figures and other "manly" men who advocate for men's health issues.

Leave these on the kitchen counter or on his desk or dresser, without comment.

But don't ask him whether he's read them.

That's nagging.

Copyright © 2006, Orlando Sentinel | Get home delivery - up to 50% off Partners...